Literature DB >> 30480590

Eosinophilic colitis and colonic eosinophilia.

Marjorie M Walker1, Michael D Potter, Nicholas J Talley.   

Abstract

PURPOSE OF REVIEW: Eosinophilic colitis is a rare condition, with a prevalence rate in the USA of 2-3/100 000 persons (0.003%), but diagnosed in 0.1% of biopsies in those colonoscoped for diarrhoea. Secondary colonic eosinophilia is more common and associated with systemic, colonic and infectious diseases. In this review, the latest advances in diagnosis, treatment and prognosis are summarized and discussed. RECENT
FINDINGS: What constitutes a 'normal' count of eosinophils is poorly documented but there are recent studies that establish normal colonic eosinophil ranges as well as distinguishing histological and clinical findings in primary eosinophilic colitis and secondary colonic eosinophilia in children and adults. Primary eosinophilic colitis is rare, relatively straightforward to diagnose, but may be difficult to treat. Colonic eosinophilia may be overt in parasite infection and connective tissue disease. More subtle, secondary colonic eosinophilia is a useful biomarker for gastrointestinal diseases, such as inflammatory bowel disease, colonic spirochaetosis and collagenous colitis, but the eosinophilia may more often be overlooked. A limited number of drugs are also known to cause left sided colonic eosinophilia such as clopidogrel, ibuprofen and oestroprogestinic agents.
SUMMARY: Advances in our understanding of primary eosinophilic colitis and secondary colonic eosinophilia is progressing and if present, colonic eosinophilia should point the clinician and pathologist to a list of differential diagnoses worth considering to direct optimal management.

Entities:  

Year:  2019        PMID: 30480590     DOI: 10.1097/MOG.0000000000000492

Source DB:  PubMed          Journal:  Curr Opin Gastroenterol        ISSN: 0267-1379            Impact factor:   3.287


  4 in total

1.  Mucosal Eosinophilia Is an Independent Predictor of Vedolizumab Efficacy in Inflammatory Bowel Diseases.

Authors:  Erin M Kim; Cara Randall; Renee Betancourt; Staci Keene; Amy Lilly; Mark Fowler; Evan S Dellon; Hans H Herfarth
Journal:  Inflamm Bowel Dis       Date:  2020-07-17       Impact factor: 5.325

2.  Benralizumab Completely Depletes Gastrointestinal Tissue Eosinophils and Improves Symptoms in Eosinophilic Gastrointestinal Disease.

Authors:  Fei Li Kuang; Michelly Sampaio De Melo; Michelle Makiya; Sheila Kumar; Thomas Brown; Lauren Wetzler; JeanAnne M Ware; Paneez Khoury; Margaret H Collins; Martha Quezado; Stefania Pittaluga; Amy D Klion
Journal:  J Allergy Clin Immunol Pract       Date:  2022-03-10

3.  Evaluating Eosinophilic Colitis as a Unique Disease Using Colonic Molecular Profiles: A Multi-Site Study.

Authors:  Tetsuo Shoda; Margaret H Collins; Mark Rochman; Ting Wen; Julie M Caldwell; Lydia E Mack; Garrett A Osswald; John A Besse; Yael Haberman; Seema S Aceves; Nicoleta C Arva; Kelley E Capocelli; Mirna Chehade; Carla M Davis; Evan S Dellon; Gary W Falk; Nirmala Gonsalves; Sandeep K Gupta; Ikuo Hirano; Paneez Khoury; Amy Klion; Calies Menard-Katcher; John Leung; Vincent A Mukkada; Philip E Putnam; Jonathan M Spergel; Joshua B Wechsler; Guang-Yu Yang; Glenn T Furuta; Lee A Denson; Marc E Rothenberg
Journal:  Gastroenterology       Date:  2022-01-25       Impact factor: 33.883

4.  Mucosal Eosinophil Abundance in Non-Inflamed Colonic Tissue Is Associated with Response to Vedolizumab Induction Therapy in Inflammatory Bowel Disease.

Authors:  Ruben Y Gabriëls; Arno R Bourgonje; Julius Z H von Martels; Tjasso Blokzijl; Rinse K Weersma; Kevin Galinsky; Julius Juarez; Klaas Nico Faber; Gursah Kats-Ugurlu; Gerard Dijkstra
Journal:  J Clin Med       Date:  2022-07-16       Impact factor: 4.964

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.